Valley National Advisers Inc. Has $3.70 Million Stock Position in Gilead Sciences, Inc. $GILD

Valley National Advisers Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,353 shares of the biopharmaceutical company’s stock after selling 1,937 shares during the quarter. Valley National Advisers Inc.’s holdings in Gilead Sciences were worth $3,697,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after buying an additional 1,520,809 shares during the last quarter. Nuveen LLC acquired a new position in shares of Gilead Sciences during the first quarter worth $620,415,000. Finally, Robeco Institutional Asset Management B.V. lifted its stake in shares of Gilead Sciences by 12.5% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 3,742,656 shares of the biopharmaceutical company’s stock valued at $414,948,000 after acquiring an additional 417,237 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the sale, the insider directly owned 113,193 shares in the company, valued at $12,855,329.01. The trade was a 2.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on GILD. Rothschild & Co Redburn boosted their price objective on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research note on Friday, July 25th. UBS Group lifted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Finally, Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $108.00 to $127.00 in a report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Stock Up 1.9%

Shares of NASDAQ:GILD opened at $112.69 on Monday. The stock has a market cap of $139.83 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 0.77 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12-month low of $83.98 and a 12-month high of $121.83. The business’s 50 day moving average is $114.34 and its 200 day moving average is $109.97.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the prior year, the company posted $2.01 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.